Epigenetic Alterations in Patients with Type 2 Diabetes Mellitus

Balkan Journal of Medical Genetics

Volumn 18, Issue 2, 2015, Pages 15-24

  Karachanak Yankova, S ^a   Dimova, R ^b   Nikolova, D ^a   Nesheva, D ^a   Koprinarova, M ^c   Maslyankov, S ^a   Tafradjiska, R ^a   Gateva, P ^a   Velizarova, M ^d   Hammoudeh, Z ^a   Stoynev, N ^b   Toncheva, D ^a   Tankova, T ^b   Dimova, I ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b University Specialized Hospital for Active Treatment in Endocrinology Acad Iv Penchev   (Bulgaria)

^c INSTITUTE OF MOLECULAR BIOLOGY   (Bulgaria)

^d UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

DNA methylation; Epigenetic changes; Methyl CpG binding domain protein 2 (MBD2); Stress and toxicity genes; Tumorigenesis; Type 2 diabetes mellitus (T2DM)

Indexed keywords

BRCA1 PROTEIN; CCND1 PROTEIN; GADD45A PROTEIN; GADD45G PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; INSIG1 PROTEIN; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; PEROXIREDOXIN 2; PROTEIN P53; RARA PROTEIN; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR CLASS A MEMBER 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; STRESS;

EID: 84969248876     PISSN: None     EISSN: 13110160     Source Type: Journal    
DOI: 10.1515/bjmg-2015-0081     Document Type: Article

References (32)

1. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet β cells in diabetes. J Biol Chem. 2004; 279(41): 42351-42354.
2. Hari Kumar KVS, Modi KD. Twins and endocrinology. Indian J Endocrinol Metab. 2014; 18(Suppl 1): S48-S52.
3. Bramswig NC, Kaestner KH. Epigenetics and diabetes treatment: An unrealized promise? Trends Endocrinol Met. 2012; 23(6): 286-291.
4. Kommoju U, Reddy BM. Genetic etiology of type 2 diabetes mellitus: A review. Int J Diab Dev Ctries. 2011; 31(2): 51-64.
5. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: Worthless or valuable? [Research Support, Non-U.S. Gov't Review]. Diabetes Care. 2013; 36(Suppl 2): S120-S126.
6. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. [10.1038/414782a]. Nature. 2001; 414(6865): 782-787.
7. Ling C, Groop L. Epigenetics: A molecular link between environmental factors and type 2 diabetes. Diabetes. 2009; 58(12): 2718-2725.
8. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Gene Dev. 2009; 23(7): 781-783.
9. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007; 128(4): 669-681.
10. Tsai H-C, Baylin SB. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 2011; 21(3): 502-517.
11. Patra SK, Deb M, Patra A. Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics. 2011; 2(1): 27-53.
12. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. [Research Support, Non-U.S. Gov't Review]. Trends Biochem Sci. 2006; 31(2): 89-97. doi: 10.1016/j. tibs.2005.12.008.
13. Keating ST, El-Osta A. Epigenetic changes in diabetes. [Research Support, Non-U.S. Gov't Review]. Clin Genet. 2013; 84(1): 1-10. doi: 10.1111/cge.12121.
14. Bird A. DNA methylation patterns and epigenetic memory. [Research Support, Non-U.S. Gov't Review]. Genes Dev. 2002; 16(1): 6-21.
15. Clouaire T, Stancheva I. Methyl-CpG binding proteins: Specialized transcriptional repressors or structural components of chromatin? Cell Mol Life Sci. 2008; 65(10): 1509-1522.
16. Chavali V, Tyagi N, Tyagi SC, Mishra PK. MiR-133 as an epigenetic regulator of diabetic heart failure. FASEB J. 2012; 26(1-MeetingAbstracts): 1057.1022.
17. Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: A translational prospective. J Diabetes Res. 2015; 2015: 4090842. doi: 101155/2015/490842.
18. Lindahl B. The story of growth differentiation factor 15: Another piece of the puzzle. Clin Chem. 2013; 59(11): 1550-1552.
19. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fribrilation (ARISTOTLE) trial. Circulation; 2014; 130(21): 1847-1858.
20. Al-Moghrabi N, Nofel A, Al-Yousef N, Madkhali S, Bin Amer SM, Alaiya A, et al. The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females. [Research Support, Non-U.S. Gov't]. BMC Cancer. 2014; 14: 830. doi: 10.1186/1471-2407-14-830.
21. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Blood. 2011; 117(2): 553-562.
22. Brevetti G, Schiano V, Chiariello M. Cellular adhesion molecules and peripheral arterial disease. (Review). Vasc Med. 2006; 11(1); 39-47.
23. Park JG, Yoo JY, Jeong SJ, Choi JH, Lee MR, Lee MN, et al. Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein Edeficient mice. [Research Support, Non-U.S. Gov't]. Circ Res. 2011; 109(7): 739-749.
24. Brown CO, Schibler J, Fitzgerald MP, Singh N, Salem K, Zhan F, et al. Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leukemia Res. 2013; 37(8): 963-969.
25. Scoumanne A, Chen X. Protein methylation: A new regulator of the p53 tumor suppressor. Histol Histopathol. 2008; 23(9): 1143-1149.
26. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4(3): 369-380.
27. Friberg E, Orsini N, Mantzoros C, Wolk A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia. 2007; 50(7): 1365-1374.
28. Huxley R, Ansary-Moghaddam A, Berrington De Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. (Meta-Analysis). Br J Cancer. 2005; 92(11): 2076-2083.
29. Larsson S, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: A metaanalysis. Diabetologia. 2006; 49(12): 2819-2823.
30. Larsson S, Wolk A. Diabetes mellitus and incidence of kidney cancer: A meta-analysis of cohort studies. Diabetologia. 2011; 54(5): 1013-1018.
31. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer I. 2005; 97(22): 1679-1687.
32. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta analysis. Int J Cancer. 2007; 121(4): 856-862.